Oncology Division
Alphabetical list (active faculty):   
George Ansstas

George Ansstas, MD

Associate Professor

Department of Medicine

Oncology Division

Medical Oncology

Research Interests

  • Glioblastoma genetics and epigenetics
  • Melanoma


  • 314-362-5677 (office)
  • 314-362-7086 (fax)
  • Division of Oncology
    Mail Stop 8056-0029-11
    Washington University
    660 South Euclid Avenue
    St. Louis, MO 63110
  • 11th Floor Mid-Campus Center (office)

Peer-reviewed Articles

  • Phase 3 Trial of Chemoradiotherapy With Temozolomide Plus Nivolumab or Placebo for Newly Diagnosed Glioblastoma With Methylated MGMT Promoter
    Lim M, Weller M, Idbaih A, Steinbach J, Finocchiaro G, Raval RR, Ansstas G, Baehring J, Taylor JW, Honnorat J, Petrecca K, De Vos F, Wick A, Sumrall A, Sahebjam S, Mellinghoff IK, Kinoshita M, Roberts M, Slepetis R, Warad D, Leung D, Lee M, Reardon DA, Omuro A
    Neuro Oncol 2022 May 2:noac116; [ahead of print]
  • CD33 mRNA Has Elevated Expression Levels in the Leukocytes of Peripheral Blood in Patients With Late-Onset Alzheimer's Disease
    Heidari F, Ansstas G, Ajamian F
    Gerontology 2022;68(4):421-430
  • Prolonged Response of Recurrent IDH-Wild-Type Glioblastoma to Laser Interstitial Thermal Therapy With Pembrolizumab
    Hwang H, Huang J, Khaddour K, Butt OH, Ansstas G, Chen J, Katumba RG, Kim AH, Leuthardt EC, Campian JL
    CNS Oncol 2022 Mar 1;11(1):CNS81
  • BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-Mutant Melanoma
    Mehnert JM, Mitchell TC, Huang AC, Aleman TS, Kim BJ, Schuchter LM, Linette GP, Karakousis GC, Mitnick S, Giles L, Carberry M, Frey N, Kossenkov A, Groisberg R, Hernandez-Aya LF, Ansstas G, Silk AW, Chandra S, Sosman JA, Gimotty PA, Mick R, Amaravadi RK
    Clin Cancer Res 2022 Mar 15;28(6):1098-1106
  • Biomarker-Driven Prognostication in Merkel Cell Carcinoma: A Paradigm for Personalized Therapy
    Helmink BA, Ansstas G, Fields RC
    Ann Surg Oncol 2022 Mar;29(3):1498-1501
  • Melanoma Targeted Therapies Beyond BRAF-Mutant Melanoma: Potential Druggable Mutations and Novel Treatment Approaches.�
    Khaddour K, Maahs L, Avila-Rodriguez AM, Maamar Y, Samaan S, Ansstas G
    Cancers (Basel) 2021 Nov 22;13(22):5847
  • A Phase II Study of Laser Interstitial Thermal Therapy Combined With Doxorubicin in Patients With Recurrent Glioblastoma
    Butt OH, Zhou AY, Huang J, Leidig WA, Silberstein AE, Chheda MG, Johanns TM, Ansstas G, Liu J, Talcott G, Nakiwala R, Shimony JS, Kim AH, Leuthardt EC, Tran DD, Campian JL
    Neurooncol Adv 2021 Nov 15;3(1):vdab164
  • Racial and Socioeconomic Differences in Acral Lentiginous Melanoma Outcomes: A SEER Analysis
    Raval NS, Hodges WT, Ugwu-Dike PO, Godoy F, Ansstas G, Cornelius LA, Musiek AC, Asgari MM, Semenov YR
    J Am Acad Dermatol 2021 Nov 20; [Epub ahead of print]
  • Normalization of Electroretinogram and Symptom Resolution of Melanoma-Associated Retinopathy With Negative Autoantibodies After Treatment With Programmed Death-1 (PD-1) Inhibitors for Metastatic Melanoma
    Khaddour K, Khanna S, Ansstas M, Jakhar I, Dahiya S, Council L, Ansstas G
    Cancer Immunol Immunother 2021 Sep;70(9):2497-2502
  • Targeting the IL-2 Inducible Kinase in Melanoma; a Phase 2 Study of Ibrutinib in Systemic Treatment-Refractory Distant Metastatic Cutaneous Melanoma: Preclinical Rationale, Biology, and Clinical Activity (NCI9922)
    Moschos SJ, Eroglu Z, Khushalani NI, Kendra KL, Ansstas G, In GK, Wang P, Liu G, Collichio FA, Googe PB, Carson CC, McKinnon K, Wang HH, Nikolaishvilli-Feinberg N, Ivanova A, Arrowood CC, Garrett-Mead N, Conway KC, Edmiston SN, Ollila DW, Serody JS, Thomas NE, Ivy SP, Agrawal L, Dees EC, Abbruzzese JL
    Melanoma Res 2021 Apr 1;31(2):162-172
  • Clinical Outcomes and Longitudinal Circulating Tumor DNA Changes After Treatment With Nivolumab and Olaparib in Immunotherapy Relapsed Melanoma With Detected Homologous Recombination Deficiency
    Khaddour K, Ansstas M, Ansstas G
    Cold Spring Harb Mol Case Stud 2021 Oct 19;7(5):6129
  • BRAF Mutations May Identify a Clinically Distinct Subset of Glioblastoma
    McNulty SN, Schwetye KE, Ferguson C, Storer CE, Ansstas G, Kim AH, Gutmann DH, Rubin JB, Head RD, Dahiya S
    Sci Rep 2021 Oct 8;11(1):19999
  • Salvage Therapies for Radiation-Relapsed Isocitrate Dehydrogenase-Mutant Astrocytoma and 1p/19q Codeleted Oligodendroglioma
    Ma S, Rudra S, Campian JL, Chheda MG, Johanns TM, Ansstas G, Abraham CD, Chicoine MR, Leuthardt EC, Dowling JL, Dunn GP, Kim AH, Huang J
    Neurooncol Adv 2021 Jun 18;3(1):vdab081
  • BRAF-MEK Inhibitors as Steroid-Sparing Bridge Prior to Checkpoint Blockade Therapy in Symptomatic Intracranial Melanoma
    Khaddour K, Johanns TM, Ansstas G
    Melanoma Manag 2021 Feb 15;8(2):MMT55
  • Mutation Clearance and Complete Radiologic Resolution of Immunotherapy Relapsed Metastatic Melanoma After Treatment With Nivolumab and Olaparib in a Patient With Homologous Recombinant Deficiency: Any Role for PARP Inhibitors and Checkpoint Blockade?
    Khaddour K, Ansstas M, Visconti J, Ansstas G
    Ann Oncol 2021 Feb;32(2):279-280
  • Durable Remission After Rechallenge With Ipilimumab and Nivolumab in Metastatic Merkel Cell Carcinoma Refractory to Avelumab: Any Role for Sequential Immunotherapy?
    Khaddour K, Rosman IS, Dehdashti F, Ansstas G
    J Dermatol 2021 Feb;48(2):e80-e81
  • Successful Use of BRAF/MEK Inhibitors as a Neoadjuvant Approach in the Definitive Treatment of Papillary Craniopharyngioma
    Khaddour K, Chicoine MR, Huang J, Dahiya S, Ansstas G
    J Natl Compr Canc Netw 2020 Dec 2;18(12):1590-1595
  • Successful Administration of Sequential TVEC and Pembrolizumab Followed by Temozolomide in Immunotherapy Refractory Intracranial Metastatic Melanoma With Acquired B2M Mutation
    Khaddour K, Dowling J, Huang J, Council M, Chen D, Cornelius L, Johanns T, Dahiya S, Ansstas G
    Oncotarget 2020 Dec 29;11(52):4836-4844
  • Induced Remission of Metastatic Squamous Cell Carcinoma With an Immune Checkpoint Inhibitor in a Patient With Recessive Dystrophic Epidermolysis Bullosa
    Khaddour K, Gorell ES, Dehdashti F, Tang JY, Ansstas G
    Case Rep Oncol 2020 Jul 30;13(2):911-915
  • Metachronous Cutaneous Squamous Cell Carcinoma in a Young Patient as the Only Presenting Symptom to Uncover Lynch Syndrome With MLH1 Germline Mutation
    Khaddour K, Fields RC, Ansstas M, Rosman IS, Ansstas G
    Hered Cancer Clin Pract 2020 Nov 16;18(1):23
  • The Landscape of Novel Therapeutics and Challenges in Glioblastoma Multiforme: Contemporary State and Future Directions
    Khaddour K, Johanns TM, Ansstas G
    Pharmaceuticals (Basel) 2020 Nov 14;13(11)
  • Pembrolizumab-Induced Neutrophilic Dermatosis of the Dorsal Hands
    Mayer RZ, Ansstas G, Anadkat MJ
    Oncol Case Report J 2020;3(2):1024
  • Rapid and Sustained Response to Immune Checkpoint Inhibition in Cutaneous Squamous Cell Carcinoma After Allogenic Hematopoietic Cell Transplant for Sezary Syndrome
    Khaddour K, Musiek A, Cornelius LA, Dehdashti F, Westervelt P, Fields R, Ansstas G
    J Immunother Cancer 2019 Dec 4;7(1):338
  • Clinical and Laboratory Features of Autoimmune Hemolytic Anemia Associated With Immune Checkpoint Inhibitors
    Leaf RK, Ferreri C, Rangachari D, Mier J, Witteles W, Ansstas G, Anagnostou T, Zubiri L, Piotrowska Z, Oo TH, Iberri D, Yarchoan M, Salama AKS, Johnson DB, Leavitt AD, Rahma OE, Reynolds KL, Leaf DE
    Am J Hematol 2019 May;94(5):563-574
  • Beyond Sequence Variation: Assessment of Copy Number Variation in Adult Glioblastoma Through Targeted Tumor Somatic Profiling
    McNulty SN, Cottrell CE, Vigh-Conrad KA, Carter JH, Heusel JW, Ansstas G, Dahiya S
    Hum Pathol 2019 Apr;86:170-181
  • Peritoneal Metastasis as Extramedullary Myeloma
    Toama W, Ansstas G, Stockerl-Goldstein K
    J Hematol Mult Myeloma. 2018; 3(1): 1013
  • Analysis of Point Mutations and Copy Number Variation in Grade II and III Meningioma
    McNulty SN, Schwetye K, Goldstein M, Carter J, Schmidt RE, Ansstas G, Tsien CI, Kim AH, Dahiya S
    Exp Mol Pathol 2018 Dec;105(3):328-333
  • Final Results of a Phase I Dose-Escalation, Dose-Expansion Study of Adding Disulfiram With or Without Copper to Adjuvant Temozolomide for Newly Diagnosed Glioblastoma
    Huang J, Campian JL, Gujar AD, Tsien C, Ansstas G, Tran DD, DeWees TA, Lockhart AC, Kim AH
    J Neurooncol 2018 May;138(1):105-111
  • BRAF-Targeted Therapy in the Treatment of BRAF-Mutant High-Grade Gliomas in Adults
    Johanns TM, Ansstas G, Dahiya S
    J Natl Compr Canc Netw 2018 Apr;16(4):451-454
  • Use of Extracranial Radiation Therapy in Metastatic Melanoma Patients Receiving Immunotherapy
    Gabani P, Robinson CG, Ansstas G, Johanns TM, Huang J
    Radiother Oncol 2018 May;127(2):310-317
  • Rapid Clinical and Radiographic Response With Combined Dabrafenib and Trametinib in Adults With BRAF-Mutated High-Grade Glioma
    Johanns TM, Ferguson CJ, Grierson PM, Dahiya S, Ansstas G
    J Natl Compr Canc Netw 2018 Jan;16(1):4-10
  • Impact of Concurrent Chemotherapy With Radiation Therapy for Elderly Patients With Newly Diagnosed Glioblastoma: A Review of the National Cancer Data Base
    Huang J, Samson P, Perkins SM, Ansstas G, Chheda MG, DeWees TA, Tsien CI, Robinson CG, Campian JL
    J Neurooncol 2017 Feb;131(3):593-601
  • Immunogenomics of Hypermutated Glioblastoma: A Patient With Germline POLE Deficiency Treated With Checkpoint Blockade Immunotherapy
    Johanns TM, Miller CA, Dorward IG, Tsien C, Chang E, Perry A, Uppaluri R, Ferguson C, Schmidt RE, Dahiya S, Ansstas G, Mardis ER, Dunn GP
    Cancer Discov 2016 Nov;6(11):1230-1236
  • Effect of Single-Agent Concurrent Chemotherapy on Survival in Anaplastic Oligodendroglioma: A Review of the National Cancer Data Base
    Acharya S, Perkins SM, Campian J, Ansstas G, Chheda M, Tsien CI, Robinson CG, Huang J
    Int J Radiat Oncol Biol Phys 2016 Oct 1;96(2S):E76-E77
  • Imaging Changes Following Proton Radiation Therapy in Adult Diffuse Gliomas
    Meeks M, Acharya S, Huang J, Robinson CG, Perkins SM, Campian J, Ansstas G, Kim A, Dunn G, Zhao T, Sun B, Rich K, Tsien CI
    Int J Radiat Oncol Biol Phys 2016 Oct 1;96(2S):E106
  • Treatment With Tumor-Treating Fields Therapy and Pulse Dose Bevacizumab in Patients With Bevacizumab-Refractory Recurrent Glioblastoma: A Case Series
    Ansstas G, Tran DD
    Case Rep Neurol 2016 Jan 8;8(1):1-9
  • Evolution of Definitions of Response, Progression-Free Survival and Event-Free Survival in Front-Line Studies of Chronic Myeloid Leukemia
    Ansstas G, Vij R
    Leuk Lymphoma 2012 Jul;53(7):1273-81
  • Mobilization of Hematopoietic Stem and Progenitor Cells Using Inhibitors of CXCR4 and VLA-4
    Rettig MP, Ansstas G, DiPersio JF
    Leukemia 2012 Jan;26(1):34-53
  • Efficacy and Tolerability of PTK787/ZK 222584 in a Phase II Study of Post-Transplant Maintenance Therapy in Patients With Multiple Myeloma Following High-Dose Chemotherapy and Autologous Stem Cell Transplant
    Vij R, Ansstas G, Mosley JC, Bryant G, Hassan A, Amador-Ortiz C, Procknow E
    Leuk Lymphoma 2010 Aug;51(8):1577-9

Book Chapters

  • Oncologic Emergencies
    Ansstas G
    In: The Washington Manual of Oncology, 4th Edition (Morgensztern D, Ghobadi A, Govindan R, Editors), Wolters Kluwer, Philadelphia, 2022
  • (Neuro-Oncology Chapter)
    Ansstas G
    PPO Oncology Review book. Devita book, 2016
  • (Chapters on Hematological Malignancies)
    Ansstas G
    In: The Washington Manual of Internal Medicine, Lippincott 2013
  • (Chapters on WBC Disorders, RBC Disorders, Head and Neck Cancers, Leukemia, and MPD)
    Ansstas G
    In: The Washington Manual of Hematology and Oncology Subspecialty Consult, Lippincott 2012
  • Application of CXCR4-Inhibitors in Leukemia
    Ansstas G, Mir F, Rettig MP, Schroeder M, Eissenberg L, DiPersio JF
    Springer, 2012